Inhaled Fluticasone Causes Iatrogenic Cushing’s Syndrome in Patients Treated with Ritonavir

References

• Flexner C. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000; 40:649–674.
   PubMed Web of Science ®Google Scholar
• Motwani B, Khayr W. Pharmacoenhancement of protease inhibitors. Am J Ther 2006; 13(1):57–63.
   PubMedGoogle Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(Suppl. 5):147–334.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868–875.
   PubMed Web of Science ®Google Scholar
• Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing’s syndrome in a patient treated with nasal fluticasone. AIDS 1999; 13(13):1803.
   PubMed Web of Science ®Google Scholar
• Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing’s syndrome and severe adrenal suppression in patients treated with Ritonavir and inhaled nasal Fluticasone. Sex Transm Infect 1999; 75(4):274.
   PubMedGoogle Scholar
• Clevenbergh P, Corcostegui M, Gérard D, Hieronimus S, Mondain V, Chichmanian RM, Sadoul JL, Dellamonica P. Iatrogenic Cushing’s syndrome in an HIV-infected patient treated with inhaled corticosteroids (Fluticasone propionate) and low dose Ritonavir enhanced PI containing regimen. J Infect 2002; 44(3):194–195.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Dubé MP. Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 2002; 35(6):E69–E71.
   PubMed Web of Science ®Google Scholar
• Rouanet I, Peyrière H, Mauboussin JM, Vincent D. Cushing’s syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 2003; 4(2):149–150.
   PubMedGoogle Scholar
• Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir–fluticasone interaction. Intern Med J 2005; 35(1):67–68.
   PubMedGoogle Scholar
• Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing’s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: Six cases. J Clin Endocrinol Metab 2005; 90(7):4394–4398.
   PubMed Web of Science ®Google Scholar
• Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA. Iatrogenic Cushing’s syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 2005; 19(7):740–741.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J. Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006; 148(3):386–388.
   PubMedGoogle Scholar
• Arrington-Sanders R, Hutton N, Siberry GK. Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 2006; 25(11):1044–1048.
   PubMed Web of Science ®Google Scholar
• Pessanha TM, Campos JM, Barros AC, Pone MV, Garrido JR, Pone SM. Iatrogenic Cushing’s syndrome in a adolescent with AIDSs on ritonavir and inhaled fluticasone. Case report and literature review. AIDS 2007; 21(4):529–532.
   PubMedGoogle Scholar
• Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM. Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. Ann Pharmacother 2007; 41(7):1306–1309.
   PubMed Web of Science ®Google Scholar
• Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: A review of the literature. HIV Med 2008; 9(6):389–396.
   PubMed Web of Science ®Google Scholar
• Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM. Iatrogenic Cushing’s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: Description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic) 2009; 8(2):113–121.
   PubMedGoogle Scholar
• Williams GH, Dluhy RG. Disorders of the Adrenal Cortex. Harrison’s Principles of Internal Medicine 17e. New York: McGraw-Hill, 2008.
   Google Scholar
• Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101(4):434–439.
   Google Scholar
• Molimard M, Girodet PO, Pollet C, Fourrier-Reglat A, Daveluy A, Haramburu F, Fayon M, Tabarin A. Inhaled corticosteroids and adrenal insufficiency, prevalence and clinical presentation. Drug Saf 2008; 31(9):769–774.
   PubMedGoogle Scholar
• Kedem E, Shachar E, Hassoun G, Pollack S. Iatrogenic Cushing’s Syndrome due to Coadministration of Ritonavir and Inhaled Budesonide in an Asthmatic Human Immunodeficiently Virus Infected Patient. J Asthma 2010; 47(7):830–831.
   Google Scholar
• Daveluy A, Raignoux C, Miremont-salame G, Girodet PO, Moore N, Haramburu F, Molimard M. Drug interaction between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Phamacol 2009; 65:743–745.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999; 159:941–955.
   PubMed Web of Science ®Google Scholar
• Hopkins RL, Leinung MC. Exogenous Cushing’s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 2005; 34(2):371–384.
   PubMed Web of Science ®Google Scholar
• Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 2009; 360:2328.
   PubMed Web of Science ®Google Scholar